Literature DB >> 29879374

Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes.

Valerio Chiurchiù1,2, Alessandro Leuti1,2, Reem Smoum3, Raphael Mechoulam3, Mauro Maccarrone1,2.   

Abstract

Autacoid local injury antagonist amides (ALIAmides) are a family of endogenous bioactive acyl ethanolamides that include the renowned palmitoyl ethanolamide (PEA), oleoyl ethanolamide (OEA), and stearoyl ethanolamide (SEA), and that are involved in several biologic processes such as nociception, lipid metabolism, and inflammation. The role of ALIAmides in the control of inflammatory processes has recently gained much attention and prompted the use of these molecules or their analogs, and the pharmacologic manipulation of their endogenous levels, as plausible therapeutic strategies in the treatment of several chronic inflammatory conditions. Since chronic inflammation is mainly driven by cells of adaptive immunity, particularly T lymphocytes, we aimed at investigating whether such bioactive lipids could directly modulate T-cell responses. We found that OEA, PEA, and eicosatrienoyl ethanolamide (ETEA) could directly inhibit both T-cell responses by reducing their production of TNF-α and IFN-γ from CD8 T cells and TNF-α, IFN-γ and IL-17 from CD4 T cells. Furthermore, neither SEA nor docosatrienoyl ethanolamide (DTEA) could affect cytokine production from both T cell subsets. Interestingly, unlike OEA and ETEA, PEA was also able to enhance de novo generation of forkhead box P3 (FoxP3)-expressing regulatory T cells from CD4-naive T cells. Our findings show for the first time that specific ALIAmides can directly affect different T-cell subsets, and provide proof of their anti-inflammatory role in chronic inflammation, ultimately suggesting that these bioactive lipids could offer novel tools for the management of T-cell dependent chronic inflammatory diseases.-Chiurchiù, V., Leuti, A., Smoum, R., Mechoulam, R., Maccarrone, M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes.

Entities:  

Keywords:  N-acyl ethanolamines; T cells; adaptive immunity; cytokines

Mesh:

Substances:

Year:  2018        PMID: 29879374     DOI: 10.1096/fj.201800107R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  16 in total

1.  Endocannabinoid System in Polycystic Kidney Disease.

Authors:  Jost Klawitter; Cristina Sempio; Matthew J Jackson; Peter H Smith; Katharina Hopp; Michel Chonchol; Berenice Y Gitomer; Uwe Christians; Jelena Klawitter
Journal:  Am J Nephrol       Date:  2022-03-09       Impact factor: 4.605

Review 2.  ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain.

Authors:  Ramona D'Amico; Daniela Impellizzeri; Salvatore Cuzzocrea; Rosanna Di Paola
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

3.  Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double-blind, multicentre, randomized, placebo-controlled study.

Authors:  Chiara Noli; Maria Federica Della Valle; Alda Miolo; Cristina Medori; Carlo Schievano
Journal:  Vet Dermatol       Date:  2019-06-24       Impact factor: 1.589

Review 4.  Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets.

Authors:  Alessio Filippo Peritore; Rosalba Siracusa; Rosalia Crupi; Salvatore Cuzzocrea
Journal:  Nutrients       Date:  2019-09-11       Impact factor: 5.717

5.  Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms.

Authors:  Dorian Forte; Flaminia Fanelli; Marco Mezzullo; Martina Barone; Giulia Corradi; Giuseppe Auteri; Daniela Bartoletti; Marina Martello; Emanuela Ottaviani; Carolina Terragna; Antonio Curti; Uberto Pagotto; Francesca Palandri; Michele Cavo; Lucia Catani
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

6.  Safety and efficacy of a new micronized formulation of the ALIAmide palmitoylglucosamine in preclinical models of inflammation and osteoarthritis pain.

Authors:  Marika Cordaro; Rosalba Siracusa; Daniela Impellizzeri; Ramona D' Amico; Alessio Filippo Peritore; Rosalia Crupi; Enrico Gugliandolo; Roberta Fusco; Rosanna Di Paola; Carlo Schievano; Salvatore Cuzzocrea
Journal:  Arthritis Res Ther       Date:  2019-11-28       Impact factor: 5.156

7.  Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome.

Authors:  Gil Bar-Sela; Idan Cohen; Salvatore Campisi-Pinto; Gil M Lewitus; Lanuel Oz-Ari; Ayellet Jehassi; Avivit Peer; Ilit Turgeman; Olga Vernicova; Paula Berman; Mira Wollner; Mor Moskovitz; David Meiri
Journal:  Cancers (Basel)       Date:  2020-08-28       Impact factor: 6.575

Review 8.  Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint.

Authors:  Aniello Schiano Moriello; Vincenzo Di Marzo; Stefania Petrosino
Journal:  Animals (Basel)       Date:  2022-01-31       Impact factor: 2.752

Review 9.  Phospholipid and Lipid Derivatives as Potential Neuroprotective Compounds.

Authors:  Seyed Khosrow Tayebati
Journal:  Molecules       Date:  2018-09-05       Impact factor: 4.411

10.  Analogous modulation of inflammatory responses by the endocannabinoid system in periodontal ligament cells and microglia.

Authors:  Andreas Jäger; Maria Setiawan; Eva Beins; Ingo Schmidt-Wolf; Anna Konermann
Journal:  Head Face Med       Date:  2020-11-16       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.